Listed

Comstock Inc.: Form 10-Q for the period ended Jun 30, 2023

Filed with the SEC on Aug 10, 2023 and accepted by EDGAR at Aug 10, 2023, 16:01 ET.

Share

Management's discussion and analysis

As filed, 41,186 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

RESULTS OF OPERATIONS

The following discussion and analysis provide information that management believes is relevant to an assessment and understanding of our condensed consolidated financial condition and results of operations. This discussion should be read in conjunction with the Condensed Consolidated Financial Statements included herewith, the footnotes thereto and the risk factors herein.

OVERVIEW

Comstock innovates and commercializes technologies that enable systemic decarbonization, primarily by enabling the extraction and conversion of under-utilized natural resources into renewable energy products. Our strategic plan is based on innovating, enabling and commercializing material science solutions that use our technologies to reduce reliance on long cycle fossil fuels, to shift to and maximize throughput of short cycle fuels, and to lead and support the adoption and growth of a profitable, balanced short cycle ecosystem that continuously offsets, recycles, and/or neutralizes carbon emissions.

We achieve our goal by accelerating the commercialization of our technology portfolios and investments, primarily in renewable fuels, electrification metals, and artificial intelligence enabled mineral discovery and materials development.

Comstock Fuels – Most renewable fuels draw from the same feedstock pool, primarily vegetable oils, but the total supply can only meet a small fraction of the demand. Our technologies unblock that constraint by converting abundant lignocellulosic biomass into biointermediates for refining into renewable fuels. Our team demonstrated commercial readiness with exceptional yields approaching 100 gallons of fuel per dry ton of feedstock on a gasoline gallon equivalent basis. Execution of one or more license agreements with operationally experienced, technologically sophisticated, and well capitalized customers is a top 2023 objective. Each license could create more than 20 years of recurring royalty revenue with material upfront engineering fees.

Comstock Metals – The world is focused on the production of energy generation and storage technologies to reduce reliance on fossil fuels, including lithium-ion batteries (“LIBs”), photovoltaics, and fuel cells. Each of those technologies relies on scarce critical metals, increasing global demand for primary metal mining and recycling. During 2022, we deployed a pilot system to validate technologies for use in efficiently crushing, conditioning, extracting, and recycling high purity metal concentrates from LIBs and other electronic devices. We also expanded our leadership team in metals recycling, permitted a universal waste storage facility and opportunistically entered into an agreement to sell an existing facility for net estimated cash proceeds of approximately $15.0 million. Securing revenue generating supply commitments in our expanded metals recycling business is a key objective for 2023.

Comstock Mining – We own or control twelve square miles of patented and unpatented mining claims and surface parcels, covering six and a half miles of continuous mineral strike length. We enhanced the value of a small portion of our properties in the past year with two SK-1300 technical reports estimating Measured and Indicated resources containing 605,000 ounces of gold and 5,880,000 ounces of silver, plus Inferred resources containing 297,000 ounces of gold and 2,572,000 ounces of silver. We have amassed one of the largest historical and current data repositories for the Comstock historic district and plan on enhancing that data with hyperspectral orbital imaging and generative artificial intelligence ("AI") solutions that provide prospecting analytics and enable more effective mineral discovery. Our 2023 efforts should enhance our estimated resources and advance us to a Preliminary Economic Assessment ("PEA") on the path toward full economic feasibility.

Artificial Intelligence – Quantum Generative Materials LLC ("GenMat"), our 48% owned investment, has developed and launched a new generative AI to simulate critical properties of known materials during calibration testing late last year. GenMat also plans on using its AI to simulate new material characteristics. GenMat’s generative AI models can be employed today for commercial use on GenMat’s existing high-performance computing platform, well before quantum computers become mainstream. In 2023, GenMat will, among other things, elevate new material simulation to commercial readiness by synthesizing and directly testing new AI simulated materials in high value applications. Our investment in GenMat is also an integral component of our ongoing innovation strategy.

The Company’s strategic investment in the Sierra Springs Opportunity Fund ("SSOF") and its subsidiaries further demonstrates our commitment to and support of sustainable economic growth in our northern Nevada communities.

COMPARATIVE FINANCIAL INFORMATION

Three-Months Ended June 30, 2023 Compared to Three-Months Ended June 30, 2022

Net loss for the three-months ended June 30, 2023 decreased by $8,586,008 to $5,504,589 from a loss of $14,090,597 for the comparable 2022 period. The decrease in net loss primarily resulted from a change in estimated fair value of the derivative assets of $9,754,617 with a $1,564,617 gain recorded in 2023 as compared to a $8,190,000 loss in 2022, lower research development expenses of $815,846, lower loss on investments of $298,801, and lower depreciation and amortization expense of $104,013. Variance partially offset by higher selling, general and administration expenses of $990,279, recovery of losses in 2022 related to the MCU-P note receivable of $895,204, and higher other income (expense) of $512,378 primarily due to change in estimated fair value of equity securities and investments.

Below we set forth a summary of comparative financial information for the three-months ended June 30, 2023 and 2022:

June 30, 2023 June 30, 2022 Change
Revenue $35,325 $52,925 $(17,600)
Operating expenses:
Selling, general and administrative expenses 3,498,852 2,508,573 990,279
Research and development 1,763,304 2,579,150 (815,846)
Depreciation & amortization 704,881 808,894 (104,013)
Gain on sale of equipment — — —
Total operating expenses 5,967,037 5,896,617 70,420
Loss from operations (5,931,712) (5,843,692) (88,020)
Other Income (Expense)
Gain (loss) on investments — (298,801) 298,801
Interest expense (376,161) (312,026) (64,135)
Interest income 61,018 1,491 59,527
Change in fair value of derivative instruments 1,564,617 (8,190,000) 9,754,617
Gain (loss) on conversion of debt 32,800 — 32,800
Impairment of investments and note receivable, net recovery — 895,204 (895,204)
Other income (expense) (855,151) (342,773) (512,378)
Total other income (expense), net 427,123 (8,246,905) 8,674,028
Net loss $(5,504,589) $(14,090,597) $8,586,008
Net loss attributable to noncontrolling interest $(36,101) $(323,751) $287,650
Net loss attributable to Comstock Inc. $(5,468,488) $(13,766,846) $8,298,358

RESULTS OF OPERATIONS

Three-Months Ended June 30, 2023 Compared to Three-Months Ended June 30, 2022

Revenues for the three-months ended June 30, 2023 decreased by $17,600 to $35,325 from $52,925 for the comparable 2022 period, as a result of lower revenues from operating leases on our buildings, primarily due to the sale of the Daney Ranch.

Revenue, costs of sales and gross profit in future periods will vary significantly depending on a number of factors, including the amount of renewable energy products that we produce and sell, the market prices for those products, the extent to which we secure and collect reasonable royalties, the degree to which we can provide event-driven engineering services, and the costs associated with each component of the aforementioned revenues.

Selling, general and administrative expense for the three-months ended June 30, 2023 increased by $990,279 to $3,498,852 from $2,508,573 in the comparable 2022 period, primarily as a result of higher employee costs of $1,015,169 attributed to higher payroll and related costs, executive incentive compensation and higher marketing and investor relations expenses.

Research and development expenses for the three-months ended June 30, 2023 decreased by $815,846 to $1,763,304 from $2,579,150 in the comparable 2022 period, primarily as a result of lower costs related to the accelerated development of pilot scale systems in 2022 for processing woody biomass into intermediate materials that can be converted into fuels and for crushing and separating lithium ion batteries. These systems are used to validate the processes and develop parameters for upscaling these renewable technologies. Our Comstock Fuels and Comstock Metals subsidiaries are leading the developments of these commercialized technologies. No similar costs were incurred in the first half of 2023. Variance offset partially by higher employee costs attributed to executive incentive compensation.

Depreciation and amortization for the three-months ended June 30, 2023 decreased by $104,013 to $704,881 from $808,894 in the comparable 2022 period, primarily from ceasing amortization on assets held for sale in the second quarter of 2023.

Gain on investments for the three-months ended June 30, 2023 increased by $298,801 due to no gain on investments for the three-months ended June 30, 2023 compared to a loss of $298,801 for the comparable 2022 period. The 2022 loss was primarily due to realized losses on sales of Tonogold common stock.

Interest expense for the three-months ended June 30, 2023 increased by $64,135 to $376,161 from $312,026 in the comparable 2022 period, primarily due to interest and related amortization of the original issue discount ("OID") on the GHF 2021 Note, the Alvin Fund 2022 Note and the Ionic Note, the latter of which originated during the fourth quarter of 2022.

Interest income for the three-months ended June 30, 2023 increased by $59,527 to $61,018 from $1,491 in the comparable 2022 period, as a result of $17,310 and $20,380 from interest income from Daney Ranch notes receivable and higher interest on cash held in deposits, respectively, for the three-months ended June 30, 2023.

Change in the fair value of our derivative instruments for the three-months ended June 30, 2023 increased by $9,754,617 to a gain of $1,564,617 from a loss of $8,190,000 in the comparable 2022 period, as a result of a higher increase in the Company's share price in connection with potential make-whole obligations for minimum value commitments on the Company's common shares and change in the fair value of the Ionic derivative. The 2023 gain was attributed $1,365,000 LINICO investment, $1,030,871 for GenMat investment and $585,000 Haywood investment, offset by a loss $1,416,254 on the derivative liability for Ionic Note. The loss from the three-months ended June 30, 2022 was attributed to $3,675,000 for LINICO investment, $3,150,000 for GenMat investment and $1,365,000 Haywood investment.

Gain of $32,800 on conversion of debt for the three-months ended June 30, 2023 are attributed to the Ionic Note conversions of 1,951,248 shares for the three-months ended June 30, 2023.

Recovery of impairment losses for the three-months ended June 30, 2023 decreased by $895,204, due primarily to a recovery of credit losses on the MCU-P note receivable for the three-months ended June 30, 2022. No impairment losses or recoveries were recorded in the second quarter 2023.

Other income (expenses), net for the three-months ended June 30, 2023 were $855,151, primarily consisting of losses from our equity method investments of $341,099 including a GenMat loss of $345,586, and losses from our investment in ABTC common shares of $765,000.

Other income (expenses), net for the three-months ended June 30, 2022 were $342,773, which primarily consisted of losses from our equity method investments of $311,917 and other losses of $30,856.

COMPARATIVE FINANCIAL INFORMATION

Six-Months Ended June 30, 2023 Compared to Six-Months Ended June 30, 2022

Net loss for the six-months ended June 30, 2023 decreased by $9,451,289 to $11,186,331 from a loss of $20,637,620 for the comparable 2022 period. The decrease in net loss primarily resulted from a change in estimated fair value of the derivative assets of $7,388,212 with a $2,263,212 gain recorded in 2023 as compared to losses of $5,125,000 in 2022, decrease in losses from impairment of intangible assets, notes receivable from MCU-P and investments in MCU of $3,581,685 recorded in the first half of 2022, lower research development expenses of $742,885, lower depreciation and amortization expense of $317,501 and gain on sale of equipment of $178,193. Variance partially offset by higher selling, general and administration expenses of $1,974,485, loss on conversion of debt $237,656, higher interest expense $354,589 and lower interest income $251,477.

Below we set forth a summary of comparative financial information for the six-months ended June 30, 2023 and 2022:

June 30, 2023 June 30, 2022 Change
Revenue $66,075 $107,550 $(41,475)
Operating expenses:
Selling, general and administrative expenses 6,885,824 4,911,339 1,974,485
Research and development 3,031,683 3,774,568 (742,885)
Depreciation and amortization 1,335,922 1,653,423 (317,501)
Gain on sale of equipment (178,193) — (178,193)
Total operating expenses 11,075,236 10,339,330 735,906
Loss from operations (11,009,161) (10,231,780) (777,381)
Other Income (Expense)
Gain (loss) on investments — 52,823 (52,823)
Interest expense (991,339) (636,750) (354,589)
Interest income 106,875 358,352 (251,477)
Change in fair value of derivative instruments 2,263,212 (5,125,000) 7,388,212
Gain (loss) on conversion of debt (237,656) — (237,656)
Recovery (Impairment) of intangible assets — (338,034) 338,034
Impairment of investments and note receivable, net recovery — (3,243,651) 3,243,651
Other income (expense) (1,318,262) (1,473,580) 155,318
Total other income (expense), net (177,170) (10,405,840) 10,228,670
Net loss (11,186,331) (20,637,620) 9,451,289
Net loss attributable to noncontrolling interest (48,906) (492,219) 443,313
Net loss attributable to Comstock Inc. $(11,137,425) $(20,145,401) $9,007,976

37

RESULTS OF OPERATIONS

Six-Months Ended June 30, 2023 Compared to Six-Months Ended June 30, 2022

Revenues and gross profit for the six-months ended June 30, 2023, decreased $41,475 to $66,075 from $107,550 for the comparable 2022 period as a result of lower revenues from operating leases on our land and building leased to others, primarily due to the sale of the Daney Ranch.

Revenue, costs of sales and gross profit in future periods will vary significantly depending on a number of factors, including the amount of renewable energy products that we produce and sell, the market prices for those products, the extent to which we secure and collect reasonable royalties, the degree to which we can provide event-driven engineering services, and the costs associated with each component of the aforementioned revenues.

Selling, general and administrative expense for the six-months ended June 30, 2023 increased by $1,974,485 to $6,885,824 from $4,911,339 in the comparable 2022 period primarily as a result of higher employee costs of $1,594,695 attributed to higher salaries, executive incentive compensation, payroll administration costs and higher marketing and investor relations expenses. Other costs increased by $772,314 including mining related costs associated with no relative reimbursements from Tonogold, partially offset by lower professional fees of $418,738.

Research and development expenses for the six-months ended June 30, 2023 decreased by $742,885 to $3,031,683 from $3,774,568 in the comparable 2022 period primarily as a result of lower costs related to the development of a pilot scale system in 2022 for processing woody biomass into intermediate materials that can be converted into paper products and fuels and the pilot scale system for crushing and separating lithium ion batteries. These systems are used to validate the processes and develop parameters for upscaling these renewable technologies. Our Comstock Engineering, Comstock Innovations and LINICO subsidiaries, which were acquired in 2021 are leading the developments of these commercialized technologies. No similar costs were incurred in the first half of 2023. Variance offset partially by higher employee costs attributed to executive incentive compensation.

Depreciation and amortization during the six-months ended June 30, 2023, decreased by $317,501 to $1,335,922 from $1,653,423 in the comparable 2022 period, primarily from ceasing amortization on assets held for sale in the first half of 2023.

Gain on sale of equipment attributed to the AQMS Facility during the six-months ended June 30, 2023, attributed to the AQMS Facility was $178,193.

Gain on investments during the six-months ended June 30, 2023 decreased by $52,823 due to no gain on investments for the first half of 2023 compared to a gain of $52,823 for the comparable 2022 period. The 2022 gain was primarily a result of sales of 8,065,924 shares of Tonogold stock.

Interest expense for the six-months ended June 30, 2023, increased by $354,589 to $991,339 from $636,750 for the comparable 2022 period primarily due to interest and related amortization of the original issue discount ("OID") on the GHF promissory note, the Alvin note and the Ionic Note that originated during the fourth quarter of 2022.

Interest income for the six-months ended June 30, 2023, decreased by $251,477 to $106,875 from $358,352 in the comparable 2022 period, as a result of the extinguishment of the Tonogold note receivable and the extinguishment of the MCU-P note receivable that was exchanged for the MCU assets, both of which are no longer accruing interest income for the six-months ended June 30, 2023.

Change in fair value of our derivative instruments for the six-months ended June 30, 2023, increased by $7,388,212 to a gain of $2,263,212 in 2023 compared to a loss in 2022 of $5,125,000 as a result of an increase in the Company's share price in connection with potential make whole obligations for minimum value commitments on the Company’s common shares. The 2023 gain was attributed $1,575,000 LINICO investment, $1,189,466 for GenMat investment and $675,000 Haywood investment, offset by a loss $1,176,254 on the derivative liability for Ionic Note. The 2022 loss was attributed to $2,345,000 for LINICO investment, $2,010,000 for GenMat investment and $1,365,000 Haywood investment.

Loss of $237,656 on conversion of debt for the six-months ended June 30, 2023 are attributed to the Ionic Note conversions of 6,490,661 shares for the six-months ended June 30, 2023.

Impairment of intangible assets for the six-months ended June 30, 2023 decreased by $338,034, due primarily to the FPC intangible assets as a result of historical and continuing losses and an inability to recover the investment through the use of their technology. For the six-months ended June 30, 2023, no impairment losses or recoveries were recorded.

Impairment of investments and notes receivable, net of recoveries, for the six-months ended June 30, 2023, decreased by $3,243,651. Decrease due primarily to the 2022 impairment losses as a result of investments in MCU and MCU-P and note receivable in MCU-P, which were deemed unrecoverable as of March 31, 2022 from a significant decline in forecasted cash flows from the MCU-P operations. Variance also attributed to $595,000 related to the LPB investment prior to settlement in exchange for 3,500,000 of the Company's shares in 2022; offset by $895,204 recovery of credit losses on the MCU-P note receivable for the three-months ended June 30, 2022. For the six-months ended June 30, 2023, no impairment losses or recoveries were recorded.

Other income (expenses), net, for the six-months ended June 30, 2023 were $1,318,262, primarily consisting of losses from our equity method investments of $806,265 including a GenMat loss of $789,209 and loss from our investment in ABTC common shares of $765,000.

Other income (expenses), net, for the six-months ended June 30, 2022 were $1,473,580, primarily consisted of a reduction in value of the Tonogold note receivable of $605,000, losses from our equity method investments of $578,819, LPB settlement expense of $250,000 and other losses of $39,761.

OUTLOOK

The primary focus for 2023 has been and continues to be commercialization. The Company’s biorefining technologies are commercially ready and offer unprecedented performance for the Company’s prospective customers. Comstock Fuels is actively pursuing revenue producing opportunities with globally recognized renewable fuel producers. Comstock Metals is also commercially ready and has engineered and ordered its first commercial demonstration facility and will permit and deploy this facility in the second half of 2023. The capital expenditures for this commercial operation will be approximately $2 million.

GenMat’s physics-based, generative AI solutions has made significant technological advancements over the past two years with the 2023 goal of commercial readiness first and then followed by commercialization with early adopting customers. Comstock Mining recently secured a revenue generating license, resulting in expected 2023 cash proceeds of over $2.0 million.

Commercialization

Comstock’s team has decades of diverse technology development and commercialization experience. The Company uses a disciplined approach to devising, qualifying, and elevating innovations from conception through increasing degrees of commercial readiness. The Company has adopted a widely used Technology Readiness Level (“TRL”) measurement system for objectively assessing Comstock’s progress, risks, investment qualifications, and commercial maturity.

There are nine readiness levels on the TRL scale, starting with TRL 1. Progression up the scale requires achievement of “SMART” milestones that are Specific, Measurable, Achievable, Relevant, and Timely. Proof of concept occurs at TRL 3. TRL 4 and 5 involve increasing degrees of process validation. TRL 6 is the first true demonstration of commercial readiness. TRL 7 and 8 involve various functional prototypes and pilots with increasing fidelity and sophistication. A TRL 9 technology is commercially mature and fully deployed. Depending on the technology and other applicable factors, revenue can commence at TRL 6 for early adopting and generally sophisticated commercial clients with continued development to TRL 7, 8, and 9.

The following chart summarizes the change in TRL status over the past year, and the objectives for 2023:

Line of Business Technology 12/2021 12/2022 12/2023 Goal
Cellulosic Fuels Conversion of under-utilized woody biomass into renewable fuels at high yield TRL 4 TRL 6 TRL 7
Artificial Intelligence Generative AI that simulates new materials at exponentially increased speed TRL 3 TRL 4 TRL 6
Metals Scalable extraction of metals from electrification products TRL 2 TRL 5 TRL 6
Mining Technology Dramatically reduced exploration costs with hyperspectral imaging and AI-based analytics TRL 0 TRL 2 TRL 3

39

Comstock’s SMART milestones and commercialization process involve meticulous planning that is informed by many factors, including the total addressable markets, their growth rates and the speed that the Company can initiate and increase revenue.

Comstock Fuels

Most current forms of renewable fuel draw from the same pool of conventional feedstocks, including corn and vegetable oils in the U.S., but the entire available supply of those feedstocks could only meet a small fraction of the demand for renewable fuels. Comstock's patented and patent-pending biorefining technologies unblock that constraint by converting abundant but underutilized lignocellulosic or "woody" biomass into biointermediates for refining drop-in and other renewable fuels.

The Company’s objectives for 2023 include:

  • Executing one or more early adopter license agreements and commencing development on commercial scale projects for operationally experienced, technologically sophisticated and well capitalized customers.
  • Completion of full technical documentation and engineering submittal packages.
  • Completion of an independent lifecycle carbon analysis to prove the carbon emissions reduction benefits of the fuels produced with Comstock’s known processes.
  • Continuous operation of the integrated bio-intermediate production process at the Company’s demonstration plant for sufficient time to achieve and broadly demonstrate TRL 7.

Each license agreement for a commercial production facility could create 15 to 20 years of recurring royalty revenue.

Comstock Metals

Resource scarcity and supply are generally the main drivers presented when discussing battery recycling. From a market perspective what is often missed is that electric vehicle batteries are only one of many metals-based products that can cause a massive amount of pollution if simply landfilled at the end of life with no recovery of the underlying metal values.

Comstock Metals objectives for 2023 include:

  • Physically reposition and broaden the addressable market for commercialization of our metals recycling.
  • Advancing the technology readiness for broader material recycling, prioritizing photovoltaics.
  • Permitting the broader material recycling system, starting with photovoltaics, in northern Nevada.
  • Deploying the broader material recycling and readying it for production.

Comstock Metals has submitted all permits for operating its manufacturing facility in Silver Springs, NV, and expects receipt of permits and deployment of its operations before the end of 2023, with operations commencing in early 2024.

Comstock Mining

The Company has amassed the single largest known repository of historical and current geological data on the Comstock mineral district, including extensive geophysical surveys, geological mapping, sampling and drilling data and published updated SK-1300 technical reports on the Lucerne and Dayton resource areas.

On June 30, 2023, the Company signed a Mineral Exploration and Mining Lease Agreement (the “Mining Lease”) with Mackay Precious Metals Inc (“Mackay”). The Mining Lease provides a twenty-year term granting Mackay the rights to conduct exploration on certain of the Company’s mineral properties in Storey County. Mackay paid a lease initial fee of $1,250,000 and will make quarterly lease payments of $375,000 for the first four years, and quarterly lease payments of $250,000 thereafter. In addition, Mackay will reimburse carrying costs for the mineral properties, estimated to be $177,000 per year, and will pay an NSR royalty of 1.5% from eventual mine production from the mineral properties. Mackay also committed to expenditures of $1,000,000 per year on a cumulative basis, and increasingly detailed technical reports after the first five, ten, and fifteen years.

The Company’s objectives for 2023 include:

  • Receive cash proceeds of over $2.0 million from new mineral leases leveraging the northern Gold Hill and northern Occidental claim groups.
  • Develop, in collaboration with GenMat, a next-generation geostatistical digital twin model of the most strategic development areas, using the Company’s existing geologic and geophysical data.

The Company’s 2023 efforts will apply economic analysis to Comstock’s existing gold and silver resources progressing toward full economic feasibility.

Artificial Intelligence

Investment in physics-based, generative artificial intelligence (“AGI”) is a crucial component of Comstock’s technology innovation strategy. Quantum Generative Materials LLC ("GenMat"), develops and commercializes cutting-edge generative artificial intelligence models for the discovery and manipulation of matter. GenMat is a company that Comstock has a 48.19% investment interest. This includes AGI models that can be employed today, for commercial use on GenMat’s existing, high-performance computing platforms, well before quantum computers become mainstream.

GenMat's AGI operates similarly to the large language models widely discussed in the media today, but instead of words and language, it uses atoms and molecules to generate physical systems and harness math and science to discover new materials in an exponentially shorter time than traditional methods allow. To put this into perspective, new material discovery typically takes many years and many millions of dollars. GenMat's AGI will simulate thousands of unique new materials in seconds.

GenMat’s objectives for 2023 include:

  • Elevate new material simulation to TRL 6 by synthesizing and directly testing the AGI’s simulated materials to confirm the precision and accuracy of those simulations.
  • Launch and make operational a space-based hyperspectral imaging sensor for mineral discovery applications.
  • Commercialize an enterprise-oriented API and other physics-based AGI solutions to early adopter enterprise clients for advanced materials simulation and synthesis.

While the Company can’t be precise about exactly when GenMat will initiate revenue, GenMat’s technologies are maturing much faster than anticipated when the Company invested in GenMat in 2021.

Corporate

The Company has also made meaningful progress and expect to complete the monetization of now over $30 million in sales of our non-strategic assets during 2023, while funding our business developments and limiting our focus to the objectives above. For the six-months ended June 30, 2023, the Company received from ABTC cash proceeds of $21.0 million and a net 9,076,923 ABTC common stock and paid $12 million to purchase the AQMS Facility. We expect to sell 9,076,923 restricted shares of ABTC common shares in the third and fourth quarters of 2023 and receive, at a minimum, proceeds of $6.0 million and total net proceeds of approximately $15.0 million.

The Company also expects proceeds of approximately $0.75 million from the sale of 1,500 Green Li-ion Pte. Ltd. (“Green Li-ion”) preferred shares (representing approximately 4% of the 37,162 Green Li-ion preferred shares owned by LINICO) during the 2023 third quarter. The Company intends to sell the remaining Green Li-ion preferred shares over the next twelve months.

LIQUIDITY AND CAPITAL RESOURCES

Our financial position and liquidity are based on our net sources of capital from financing as generally compared to our net uses of capital from investing activities and ultimately, our ability to generate cash flows from our operations. Our cash balances at June 30, 2023 and December 31, 2022 were $1,585,713 and $2,521,772, respectively. The Company had current assets of $41,122,241 and current liabilities of $44,349,777, representing working capital deficit of $3,227,536 at June 30, 2023.

The current liabilities include $27.8 million of Liabilities Held for Sale representing deferred cash and stock proceeds already received from the sale of the Facility and related equipment and derivative liabilities of $7.8 million for the contingent make-whole liabilities and $1.4 million of deferred revenue representing cash received from the Mackay and ABTC lease agreements.

Our primary source of liquidity during the first six-months of 2023 was cash from asset sales and to a lesser extent, financing activities. During the six-months ended June 30, 2023, we generated $3,701,641 and $2,040,330 in cash from our investing activities and our financing activities, respectively, and we used $6,678,030 in cash in our operating activities.

During the six-months ended June 30, 2023, the Company delivered 6,490,661 shares of common stock with a fair value of $3,452,848 at an average alternate conversion price per share of $0.53 with a principal balance of $2,400,000 and accrued interest of $58,707. On April 6, 2023, Ionic returned 327,549 excess shares from equity conversions in the first quarter 2023.

During the six-months ended June 30, 2023, we issued 3,214,599 shares of common stock to Tysadco, for an aggregate sales price of $1,350,000 at an average price per share of $0.42 with $7,550,000 of remaining capacity, subject to certain restrictions.

On February 13, 2023, we entered into an equity purchase agreement (the “2023 Leviston Sales Agreement”) with Leviston Resources LLC (“Leviston”) to offer and sell registered shares of common stock at an aggregate offering price of up to $5 million from time to time, at our option, on terms we deem favorable. During the six-months ended June 30, 2023, we issued 3,495,029 shares of common stock to Leviston for an aggregate sales price of $1,300,000 at an average price per share of $0.37 with $3,700,000 of remaining capacity, subject to certain restrictions.

On December 16, 2022, the Company entered into a securities purchase agreement for an unsecured convertible promissory note (the "Ionic Note") with Ionic. with a principal amount of $3,150,000, of which $2,975,000 was funded and $175,000 was an original issue discount ("OID") and issued with a 5% OID. The full principal is due on March 16, 2024. Interest is payable monthly at a rate of 8% annually. The Convertible Note contains conversion terms that are based on percentages of trading price and volumes over defined measurement periods. The terms require the conversion option to be bifurcated as a derivative. As of June 30, 2023 and December 31, 2022, the Company bifurcated the conversion feature and recorded a derivative liability of $600,000 and $420,000, respectively, reflected in our consolidated balance sheet.

On October 25, 2022, we entered into a short-term promissory note (the "Alvin Fund 2022 Note") with Alvin Fund LLC with a principal amount of $2,000,000. In consideration of the lender providing the financing, the Company issued $250,000 in shares to the lender. The full principal is due on October 25, 2023. Interest is payable monthly at a rate of 9% annually. Prepayment is allowed in full or in part at any time without premium or penalty. The loan is secured by all the property commonly referred to as the Dayton properties. On June 21, 2023, the Company issued 270,757 shares of unregistered restricted common shares with a fair value of $107,507 to Alvin Fund LLC in lieu of payment of interest under the Alvin Fund 2022 Note.

On June 21, 2022, The Company entered into an agreement with Tysadco for the purchase of up to $10,000,000 worth of shares of the Company’s common stock from time to time, at the Company’s option. Any shares offered and sold to Tysadco will be registered for resale pursuant to a registration statement on Form S-1 filed with U.S. Securities and Exchange Commission pursuant to the Securities Act of 1933 (the “Securities Act”). The Company paid a commission of 428,571 additional shares of common stock with a fair value of $300,000 to Tysadco in connection with such sale. Sales of common stock, if any, under the Purchase Agreement are made at a 10% discount to the volume weighted average sales price of the common stock on the date that Tysadco receives such a capital call from the Company.

On April 12, 2022, the Company entered into an equity purchase agreement (the “Leviston Agreement”) with Leviston Resources LLC (“Leviston”) for the purchase of up to $10,000,000 worth of shares of the Company’s common stock from time to time, at the Company’s option, on terms deemed favorable to the Company. Any shares offered and sold are issued pursuant to the Company’s shelf registration statement on Form S-3 and the related prospectus (File No. 333-263930) filed by the Company with the U.S. Securities and Exchange Commission pursuant to the Securities Act of 1933 (the “Securities Act”). Sales of common stock, if any, under the Purchase Agreement may be made in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act, at a discount of 10% to the volume weighted average sales price of the common stock on the date that Leviston receives a capital call from the Company. For consideration to enter the Leviston Agreement, the Company agreed to deliver additional shares of common stock to Leviston, for no additional consideration, on the first settlement date with respect to a put notice delivered by the Company. As of December 31, 2022, the 2022 Leviston Agreement has no remaining capacity, and the facility was closed.

We intend to fund our operations over the next twelve months from existing cash and cash equivalents, planned sales of non-strategic assets and other investments, leasing cash inflows on certain mineral properties, planned licensing, sales and profits from our cellulosic and battery metal recycling technology and related engineering services, and previously funded capital into our LINICO subsidiary and Quantum investment. Based on these expected funding sources, management believes we will have sufficient funds to sustain our operations and meet our commitments under our investment agreements during the twelve months following the date of issuance of the condensed consolidated financial statements included herein. While we have been successful in the past in obtaining the necessary capital to support our operations, including registered equity financings from our existing shelf registration and other registration statements, non-registered equity placements, borrowings and various other means. There is no assurance we will be able to obtain additional equity capital or other financing, if needed.

Net cash used in operating activities for the six-months ended June 30, 2023 decreased by $1,036,673 to $6,678,030 from $7,714,703 in the comparable 2022 period, due primarily to changes in operating expenses discussed in Financial Condition and Results of Operating Information.

Net cash provided by investing activities for the six-months ended June 30, 2023 increased by $3,185,496 to $3,701,641 from $516,145 in the comparable 2022 period, primarily due to proceeds from sale of the AQMS lease and related assets of $21.0 million, partially offset by $12.0 million in cash used for the purchase of the AQMS Facility, $3.5 million for payments on contractual commitments for GenMat, LINICO and Haywood investments, $0.9 million for SSOF advances, and $0.8 million for the purchase of water rights as compared to net cash provided in the 2022 period primarily from $0.9 million from recovery of MCU funds, $0.9 million from the sale of Tonogold common shares, and $0.8 million from Tonogold option agreement proceeds, partially offset by $0.8 million for GenMat investments, $0.5 million for licenses and $0.6 million for purchases of equipment.

Net cash provided in financing activities for the six-months ended June 30, 2023 decreased $3,591,355 to $2,040,330 from $5,631,685 for the comparable 2022 period, primarily as a result of net proceeds from the issuance of common stock of $2,810,000 and reduced contributions of $500,000 from AQMS for additional shares in LINICO in 2022.

Risks to our liquidity could result from future operating expenditures above management’s expectations, including but not limited to research and development, pre-development, exploration, selling, general and administrative, and investment related expenditures in excess of repayments of the advances to SSOF, and cash proceeds from the sale of our non-strategic assets and other investments, amounts to be raised from the issuance of equity under our existing shelf and other registration statements, declines in the market value of properties planned for sale, or declines in the share price of our common stock that would adversely affect our results of operations, financial condition and cash flows. If we were unable to obtain any necessary additional funds, this could have an immediate material adverse effect on liquidity and raise substantial doubt about our ability to continue as a going concern. In such case, we could be required to limit or discontinue certain business plans, activities or operations, reduce or delay certain capital expenditures or investments, or sell certain assets or businesses. There can be no assurance that we would be able to take any such actions on favorable terms, in a timely manner, or at all.

CRITICAL ACCOUNTING ESTIMATES

There have been no significant changes to the critical accounting estimates disclosed in Management's Discussion and Analysis of Financial Condition and Results of Operations in our 2022 Form 10-K.

Market risk

As filed, 755 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Market Prices

Changes in the market price of commodities, including precious metals, critical metals and oil and gas may significantly affect our future profitability and cash flow. Metal prices fluctuate widely due to factors such as: demand, global mine production levels, supply chain constraints, investor sentiment, central bank reserves, global conflicts and the value of the U.S. dollar.

Interest Rate Risk

The interest rates on our existing long-term debt borrowings are fixed, and as a result, interest due on borrowings are not impacted by changes in market-based interest rates.

There have been no material changes in the market risks discussed in Item 7A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Controls and procedures

As filed, 1,869 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

A. Disclosure

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, with the participation of our Principal Executive and Financial and Accounting Officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 ("Exchange Act") was conducted. Our disclosure controls and procedures are designed to ensure information required to be disclosed in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Exchange Act rules, and such information is accumulated and communicated to our management, including our Principal Executive and Financial Officer, to allow timely decisions regarding required disclosures. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based on that evaluation, our CEO concluded that our disclosure controls and procedures, including controls and procedures designed to ensure that information required to be disclosed by us is accumulated and communicated to our management (including our CEO), were effective as of June 30, 2023, in assuring them in a timely manner that material information required to be disclosed in this report has been properly recorded, processed, summarized and reported.

Changes in Internal Control Over Financial Reporting

During the quarter ended June 30, 2023, there was no change in our internal control over financial reporting that materially affected or is reasonably likely to materially affect our internal control over financial reporting.

Risk factors

As filed, 246 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

No new risk factors have been identified in addition to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022 and our Quarterly Report on Form 10-Q for the interim period ended June 30, 2023.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-04-01 to 2023-06-30$35.3kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2023-01-01 to 2023-06-30$66.1kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2023-04-01 to 2023-06-30$1.8mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2023-01-01 to 2023-06-30$3.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2023-04-01 to 2023-06-30$3.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2023-01-01 to 2023-06-30$6.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-04-01 to 2023-06-30−$5.9mus-gaap:OperatingIncomeLoss
Operating income6 months2023-01-01 to 2023-06-30−$11.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-04-01 to 2023-06-30$376.2kus-gaap:InterestExpense
Interest expense6 months2023-01-01 to 2023-06-30$991.3kus-gaap:InterestExpense
Net income3 months2023-04-01 to 2023-06-30−$5.5mus-gaap:NetIncomeLoss
Net income6 months2023-01-01 to 2023-06-30−$11.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-04-01 to 2023-06-30−$0.05us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2023-01-01 to 2023-06-30−$0.11us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-04-01 to 2023-06-30−$0.05us-gaap:EarningsPerShareBasic
Basic EPS6 months2023-01-01 to 2023-06-30−$0.11us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-04-01 to 2023-06-30101,374,933 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2023-01-01 to 2023-06-3098,173,844 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2023-01-01 to 2023-06-30−$6.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2023-04-01 to 2023-06-30$28.0kus-gaap:PaymentsToAcquireProductiveAssets
Capital expenditure6 months2023-01-01 to 2023-06-30$816.1kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2023-06-30$1.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-06-30$41.1mus-gaap:AssetsCurrent
Total assetsAt period end2023-06-30$105.0mus-gaap:Assets
Current liabilitiesAt period end2023-06-30$44.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-06-30$53.9mus-gaap:Liabilities
Long-term debtAt period end2023-06-30$3.7mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2023-06-30$2.6mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2023-06-30$48.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001120970-23-000052. Last ingested by Listed: Nov 4, 2026, 17:20 ET. Listed shows no prices and gives no investment advice.